Astellas Pharma U.S., Inc.

Antifungal agent Mycamine available to physicians

Published in Nursing Home and Elder Business Week, June 19th, 2005

Astellas Pharma U.S., Inc., announced the launch and availability of their newest systemic antifungal agent Mycamine (micafungin sodium) for injection to hospitals nationwide.

The U.S. Food and Drug Administration approved Mycamine in March 2005 for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and the treatment of esophageal candidiasis.

Mycamine is the first product to be launched by Astellas Pharma U.S., Inc., which was recently formed through the merger of Fujisawa Healthcare, Inc., and Yamanouchi Pharma America, Inc.

"The launch and availability of Mycamine, an important...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Nursing Home and Elder Business Week

Source: Nursing Home and Elder Business Week (2005-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry